This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
by Zacks Equity Research
Gain Therapeutics (GANX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
by Zacks Equity Research
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -87.88% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -3.85% and 69.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?